Drug Profile
Research programme: mitogen-activated protein kinase inhibitors - Roche
Alternative Names: MAPK inhibitors - Roche; RO 4927350; RO 5068760Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche
- Class
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 19 Nov 2009 Preclinical trials in Cancer in USA (PO)